J 2023

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

CHATZIKONSTANTINOU, Thomas; Lydia SCARFÒ; Georgios KARAKATSOULIS; Eva MINGA; Dimitra CHAMOU et. al.

Základní údaje

Originální název

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

Autoři

CHATZIKONSTANTINOU, Thomas; Lydia SCARFÒ; Georgios KARAKATSOULIS; Eva MINGA; Dimitra CHAMOU; Gloria IACOBONI; Jana KOTAŠKOVÁ; Christos DEMOSTHENOUS; Lukas SMOLEJ; Stephen MULLIGAN; Miguel ALCOCEBA; Salem AL-SHEMARI; Thérèse AURRAN-SCHLEINITZ; Francesca BACCHIARRI; Mar BELLIDO; Fontanet BIJOU; Anne CALLEJA; Angeles MEDINA; Mehreen Ali KHAN; Ramona CASSIN; Sofia CHATZILEONTIADOU; Rosa COLLADO; Amy CHRISTIAN; Zadie DAVIS; Maria DIMOU; David DONALDSON; Gimena Dos SANTOS; Barbara DRETA; Maria EFSTATHOPOULOU; Shaimaa EL-ASHWAH; Alicia ENRICO; Alberto FRESA; Sara GALIMBERTI; Andrea GALITZIA; Rocío GARCÍA-SERRA; Eva GIMENO; Isabel GONZÁLEZ-GASCÓN-Y-MARÍN; Alessandro GOZZETTI; Valerio GUARENTE; Romain GUIEZE; Ajay GOGIA; Ritu GUPTA; Sean HARROP; Eleftheria HATZIMICHAEL; Yair HERISHANU; Hernández-Rivas JOSÉ-ÁNGEL; Luca INCHIAPPA; Ozren JAKSIC; Susanne JANSSEN; Elżbieta KALICIŃSKA; Laribi KAMEL; Volkan KARAKUS; Arnon P KATER; Bonnie KHO; Maria KISLOVA; Eliana KONSTANTINOU; Maya KOREN-MICHOWITZ; Ioannis KOTSIANIDIS; Robert J KREITMAN; Jorge LABRADOR; Deepesh LAD; Levin MARK-DAVID; Ilana LEVY; Thomas LONGVAL; Alberto LOPEZ-GARCIA; Juan MARQUET; Lucia MARTIN-RODRÍGUEZ; Marc MAYNADIÉ; Stanislava MASLEJOVA; Carlota MAYOR-BASTIDA; Biljana MIHALJEVIC; Ivana MILOSEVIC; Fatima MIRAS; Riccardo MOIA; Marta MORAWSKA; Roberta MURRU; Uttam Kumar NATH; Almudena NAVARRO-BAILÓN; Ana C OLIVEIRA; Jacopo OLIVIERI; David OSCIER; Irina PANOVSKA-STAVRIDIS; Maria PAPAIOANNOU; Tomas PAPAJÍK; Zuzana KUBOVA; Punyarat PHUMPHUKHIEO; Cheyenne PIERIE; Anna PUIGGROS; Lata RANI; Gianluigi REDA; Gian Matteo RIGOLIN; Rosa RUCHLEMER; Marcos Daniel de Deus SANTOS; Mattia SCHIPANI; Annett SCHIWITZA; Yandong SHEN; Martin SIMKOVIC; Svetlana SMIRNOVA; Dina Sameh Abdelrahman SOLIMAN; Martin SPACEK; Tamar TADMOR; Kristina TOMIC; Eric TSE; Theodoros VASSILAKOPOULOS; Andrea VISENTIN; Candida VITALE; Julia von TRESCKOW; George VRACHIOLIAS; Vojin VUKOVIC; Renata WALEWSKA; Ewa WASIK-SZCZEPANEK; Zhenshu XU; Munci YAGCI; Lucrecia YAÑEZ; Mohamed YASSIN; Jana ZUCHNICKA; Maria ANGELOPOULOU; Darko ANTIC; Bella BIDERMAN; Mark CATHERWOOD; Rainer CLAUS; Marta COSCIA; Antonio CUNEO; Fatih DEMIRKAN; Blanca ESPINET; Gianluca GAIDANO; Olga B KALASHNIKOVA; Luca LAURENTI; Eugene NIKITIN; Gerassimos A PANGALIS; Panagiotis PANAGIOTIDIS; Viola Maria POPOV; Sarka POSPISILOVA; Paolo SPORTOLETTI; Niki STAVROYIANNI; Constantine TAM; Livio TRENTIN; Anastasia CHATZIDIMITRIOU; Francesc BOSCH; Michael DOUBEK; Paolo GHIA a Kostas STAMATOPOULOS

Vydání

EClinicalMedicine, AMSTERDAM, ELSEVIER, 2023, 2589-5370

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 9.600

Kód RIV

RIV/00216224:14110/23:00133207

Organizační jednotka

Lékařská fakulta

UT WoS

001158119100001

EID Scopus

2-s2.0-85178913085

Klíčová slova anglicky

Chronic lymphocytic leukemia; Other malignancies; Other cancers; Second primary malignancies

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 1. 8. 2024 09:13, Mgr. Eva Dubská

Anotace

V originále

Background Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed treatment is still unclear and represents the focus of this work. Methods We conducted a retrospective international multicenter study to assess the incidence of OMs and detect potential risk factors in 19,705 patients with CLL, small lymphocytic lymphoma, or high-count CLL-like monoclonal B-cell lymphocytosis, diagnosed between 2000 and 2016. Data collection took place between October 2020 and March 2022. Findings In 129,254 years of follow-up after CLL diagnosis, 3513 OMs were diagnosed (27.2 OMs/1000 person-years). The most common hematological OMs were Richter transformation, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Non-melanoma skin (NMSC) and prostate cancers were the most common solid tumors (STs). The only predictor for MDS and AML development was treatment with fludarabine and cyclophosphamide with/without rituximab (FC ± R) (OR = 3.7; 95% CI = 2.79–4.91; p < 0.001). STs were more frequent in males and patients with unmutated immunoglobulin heavy variable genes (OR = 1.77; 95% CI = 1.49–2.11; p < 0.001/OR = 1.89; 95% CI = 1.6–2.24; p < 0.001). CLL-directed treatment was associated with non-melanoma skin and prostate cancers (OR = 1.8; 95% CI = 1.36–2.41; p < 0.001/OR = 2.11; 95% CI = 1.12–3.97; p = 0.021). In contrast, breast cancers were more frequent in untreated patients (OR = 0.17; 95% CI = 0.08–0.33; p < 0.001). Patients with CLL and an OM had inferior overall survival (OS) than those without. AML and MDS conferred the worst OS (p < 0.001). Interpretation OMs in CLL impact on OS. Treatment for CLL increased the risk for AML/MDS, prostate cancer, and NMSC. FCR was associated with increased risk for AML/MDS.

Návaznosti

LX22NPO5102, projekt VaV
Název: Národní ústav pro výzkum rakoviny (Akronym: NÚVR)
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Národní ústav pro výzkum rakoviny, 5.1 EXCELES